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Purpose. People with long-term mental health problems are heavier smokers than the
general population, and suffer greater smoking-related morbidity and mortality. Little is
known about the effectiveness of psychological smoking cessation interventions for this
group. This review evaluates evidence from randomized controlled trials (RCTs) on the
effectiveness of psychological interventions, used alone or with pharmacotherapy, in
reducing smoking in adults with mental health problems.
Methods. We searched relevant articles between January 1999 and March 2019 and
identified 6,200 papers. Two reviewers screened 81 full-text articles. Outcomemeasures
included number of cigarettes smoked per day, 7-day point prevalence abstinence, and
continuous abstinence from smoking.
Results. Thirteen RCTs, involving 1,497 participants, met the inclusion criteria.
Psychological interventions included cognitive behavioural therapy (CBT), motivational
interviewing (MI), counselling, and telephone smoking cessation support. Three trials
resulted in significant reductions in smoking for patients receiving psychological
interventions compared with controls. Two trials showed higher 7-day point prevalence
in intervention plus nicotine replacement therapy (NRT) versus standard care groups.
Four trials showed that participants who combined pharmacotherapy (bupropion or
varenicline) with CBT were more likely to reduce their smoking by 50% than those
receiving CBT only. Four out of five trials that compared different psychological
interventions (with or without NRT) had positive outcomes regardless of intervention
type.
Conclusions. This study contributes to our understanding in a number of ways: The
available evidence is consistent with a range of psychological interventions being
independently effective in reducing smoking by people with mental health problems;
however, too few well-designed studies have been conducted for us to be confident
about, for example, which interventions work best for whom, and how they should be
implemented. Evidence is clearer for a range of psychological interventions – including
CBT,MI, and behavioural or supportive counselling – being effectivewhen usedwithNRT
or pharmacotherapy. Telephone-based and relatively brief interventions appear to be as
effective as more intense and longer-term ones. There is also good evidence for a strong
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dose-response relationship – increased attendance predicts improved outcomes – and
for interventions having more positive than negative effects on psychiatric symptoms.
Statement of contribution
What is already known on this subject? Smokers with mental health problems are more likely to suffer from smoking-related illnesses and
die at a younger age than those without mental health problems
 Although pharmacotherapy is promising, the effectiveness of psychological interventions on
smoking cessation remains unclear
What does this study add? Some psychological interventions are effective when used in combination with NRT or
pharmacotherapy
 There is a strong dose-response relationship: increased engagement with psychological treatments
predicts positive outcomes
 Short individual sessions and telephone-based support are as effective as more intense, face-to-
face, and long-term treatments
 Smoking cessation in people with mental health problems results in either no change,
or improvement in psychiatric symptoms
Smoking prevalence and levels of nicotine dependence are much higher in adults with a
long-standing mental health problem than in the general population (National Centre for
Social Research, 2015). Although smoking prevalence in the general adult populations of
mostWestern countries has declined considerably in recent years – for example from 46%
in 1976 to 16% in 2016 in the United Kingdom (Office for National Statistics, 2017), and
from 20.9% in 2005 to 15.5% in 2016 in the United States (Jamal, Phillips, Gentzke et al.,
2016) – it remains high among adults with mental health problems. In the United
Kingdom, of patients with a mental health diagnosis, around 30–37% are smokers (The
Royal College of Physicians, 2013; Royal College of Physicians and Royal College of
Psychiatrists, 2013). For patients with schizophrenia, the smoking prevalence is as high as
45% (Szatkowski & McNeill, 2013), while the severity of a mental health condition can
further increase the likelihood of smoking and addiction (Vanable, Carey, Carey, &Maisto,
2003). This association between smoking and mental health problems is also evident in
Spain, United States, and Australia (de Leone, Kiaz, Rogers, Browne, & Dinsmore, 2002;
Farrell et al., 2001; Jorm, Rodgers, Jacomb, Christenson, Henderson, & Korten, 1999). In
the United States, adults with a psychiatric diagnosis are three times more likely to smoke
than adults with no diagnosis and are much less likely to quit (Smith, Mazure, & McKee,
2014).
Studies in the United Kingdom and United States also suggest that people with severe
mental health problems are more likely to suffer from smoking-related illnesses such as
cardiovascular disease and cancer, and to die at a younger age, compared with those
without mental health problems (Colton & Manderscheid, 2006; Lawrence, Mitrou, &
Zubrick, 2009;Osborn, Levy, Nazareth, Peterson, Islam, &King, 2007). It is estimated that
current smokers with mental health problems lose 14.9 years of life relative to non-
smokers without a mental illness, and smoking accounts for up to two-thirds of the
difference in life expectancy between these two groups (Tam, Warner, & Meza, 2016).
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This problem also has serious financial implications: In England, the Royal College of
Physicians (2013) reported that smoking-related illnesses in people with mental health
problems cost the National Health Service (NHS) approximately £720 million each year,
and the global cost of smoking, including the related expenses, reaches $1 trillion annually
(Taylor, McNeill, Girling, Farley, Lindson-Hawley, & Aveyard, 2014; U.S. National Cancer
Institute and World Health Organization, 2016). There is therefore an urgent need to
address smoking and related illnesses in patients with mental health problems and
improve the support provided to them.
The National Institute for Health and Care Excellence in England (NICE, 2013) and the
US Department of Health and Human Services (DHHS, 2008) recommend that mental
health service users who smoke are offered tobacco dependence treatment advice,
including pharmacotherapy, psychological support, and practical counselling to aid
quitting. However, support for smoking cessation is not offered or implemented
consistently and to the same level across all mental health services (Ratschen, Britton, &
McNeill, 2009).
The 2010 Health Survey for England (National Centre for Social Research, 2015)
reported that two-thirds of all smokers with mental health problems would like to quit.
However, these smokers are more likely to be heavily addicted and face barriers in
successfully quitting smoking compared with those without mental health problems
(Brody et al., 2017; Fagerstr€om, & Aubin, 2009; Royal College of Physicians and Royal
College of Psychiatrists, 2013). In smoke-free psychiatric units, many patients manage to
abstain from smoking, especially with the provision of nicotine replacement therapy
(NRT), but within five weeks of being discharged the majority start smoking again
(Prochaska, Fletcher, Hall, & Hall, 2006).
One barrier is that adults with mental health problems are less likely to be offered
systematic support for smoking cessation than those in the general population (Ratschen,
Britton, Doody, & McNeil, 2016; Rethink, 2013). Despite the strong association between
smoking and poormental health,many smokers believe that smoking offersmental health
benefits by alleviating feelings of depression, stabilizing mood, and relieving stress. Thus,
smokers – and many health professionals – are often reluctant to engage in smoking
cessation interventions due to the misconception that smoking mitigates psychiatric
symptoms (Ratschen et al., 2016; Taylor et al., 2014). Moreover, smoking continues to be
condoned in many mental health settings to support social interaction or as part of a
shared smoking culture between staff and patients (Kelly, 2012; Ratschen et al., 2016).
Mental health professionals often use cigarettes as positive reinforcement for managing
behaviour and regard smoking as a legitimate coping mechanism or means of self-
medication (Hahn et al., 2013; Lawn & Condon, 2006).
However, there is no evidence to support these negative attitudes towards smoking
cessation that are often shared by patients with mental health problems and staff.
Peckham, Brabys, Cook, Tew, and Gilbody (2017) found that pharmacotherapy, in
particular the use of varenicline and bupropion, can be an effective smoking cessation aid
not only for smokers in the general population but also for thosewith severemental health
problems. Furthermore, themental health benefits of smoking cessation are as significant
for smokers with psychiatric disorders as for those without: Smoking cessation is
associatedwith reduceddepression, anxiety and stress, improvedmood, andquality of life
(Taylor et al., 2014).
Although the current evidence for the effectiveness of pharmacotherapy (e.g.,
bupropion or varenicline) on smoking cessation in smokers with mental health problems
is promising, the effectiveness of psychological interventions such as supportive
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counselling or cognitive behavioural therapy (CBT) remains unclear and has become the
focus of ongoing research (Peckham et al., 2017; Ratschen et al., 2016; Taylor et al.,
2014). Tsoi, Porwal, and Webster (2013) found that, although contingent reinforcement
(CR) with money had a short-term benefit, there was no evidence of other psychosocial
interventions resulting in reduced smoking by people with schizophrenia. Peckham et al.
(2017) reported mixed results on the effectiveness of smoking cessation programmes,
with some studies indicating positive, and some negative, outcomes. Differences have
been attributed to the varied settings, diagnoses, delivery modes, and fidelity of
professionals delivering psychological interventions.
Therefore, it remains unclear what type of support – pharmacological, psychological
or a combination of the two – ismost effective for smoking cessation and forwhich patient
group. It is also unclear whether long-term and intense face-to-face psychological
interventions aremore, less, or equally effective,when comparedwith brief or telephone-
based interventions. Addressing these important questions has the potential to improve
patient and clinician choice, and the cost-effectiveness of interventions for smoking
cessation. For example, if brief psychological interventions are effective, then patients
could be offered cheaper and possibly safer treatments than pharmacotherapy.
This review of randomized controlled trials (RCTs) examined whether – and if so,
which – psychological interventions are effective, either alone or with pharmacotherapy,
in reducing smoking in adults with mental health problems. We asked five research
questions:
RQ1. Are psychological interventions independently effective?
RQ2. Are psychological interventions plus NRT effective?
RQ3. Are psychological interventions combinedwith pharmacotherapymore effective
than psychological interventions alone?
RQ4. Which psychological interventions are most effective?
RQ5. What is the impact of psychological interventions on clinical symptoms?
Method
This review followed the PRISMA statement for reporting systematic reviews (Liberati,
Altman, Tetzlaff,Murlow,Gotzsche, Ioannidis, Clarke et al., 2009). Inclusion criteriawere
specified in advance and documented in a published protocol registered as
CRD42014014159 and available at http://www.crd.york.ac.uk/PROSPERO/ (Prospero,
2013).Methods of analysis were not decided in advance as itwas unknownwhethermeta-
analysis would be appropriate.
Search strategy
Research studies were identified by searching electronic databases, scanning contents,
and reference lists, and contacting relevant researchers where necessary. Databases were
selected to best represent source material in the fields of health psychology and public
health: These were CINAHL Plus, MEDLINE, AMED, PsycINFO via EBSCOhost, EMBASE
via OVID, PubMed, and Cochrane Library. The limits used on all databases were 1999 to
March 2019. Searches occurred between May 2014 and March 2019 and were limited to
publications in English. Search terms included psychological interventions, smoking,
cessation, and mental health problems. Full search terms are given in Appendix S1.
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Two experts were contacted via email to ascertain whether they had any published or
unpublished work relevant to the research questions that they were willing to share. One
provided us with a previously published paper, and the other did not respond. Grey
literature was also searched using ‘Open Grey’. The contents pages of the Journal of
Smoking Cessationwere screened for eligible papers from the journal’s inception inMay
2009. Reference lists including studies on smoking cessation interventions with adults
with mental health problems were also scanned.
Inclusion criteria
Population
Studies were eligible if they included adults (over 16 years of age) who had been
diagnosed with, and/or were currently receiving treatment, for a mental health problem
recognized by DSM-IV or ICD-10 with the exception of addiction and substance-related
disorders. Mental health problems are characterized by ‘a combination of abnormal
thoughts, behaviours, emotions and relationships with others’ (World Health Organisa-
tion, 2014) and present as a wide array of diagnoses including depression, schizophrenia,
and anxiety. This review was restricted to individuals over 16 years of age, below which
cessation interventions are unlikely to be offered. Studies were considered if people were
clinically stable and treated in the community, at home, as inpatients or outpatients. Only
studies involving people who reported being regular/daily smokers (i.e., five or more
cigarettes a day)were eligible since 45%of people smoking fewer than five cigarettes a day
tend to quit without intervention (Kenford,Wetter, Welsch, Smith, Fiore, & Baker, 2005).
Type of study
Only RCTs and pilot RCTs were considered for their good internal validity and lower risk
of bias than other study designs (Prospero, 2013). Published and unpublished RCTs were
considered, but only published ones met the inclusion criteria. Only studies conducted
from 1999 onwards were included. According to Peckham et al. (2017), the first trial of a
smoking cessation intervention in adults with mental health problems was published in
theUnited States in 1999.Moreover, the release in 1998 of thewhite paper ‘SmokingKills’
(The StationeryOffice, 1998) resulted in the development ofNHS Smoking Services across
England. Prior to this, ‘stop smoking’ services were not compulsory so it is unlikely that
many cessation interventions were used by smokers with mental health problems.
Interventions
Studies involving psychological interventions for smoking cessation or relapse prevention
were considered, including motivational interviewing, educational strategies, CBT,
coping skills training, behavioural skills training, and thought restructuring (we refer to
these as different ‘types’ of psychological intervention). Combination interventions, such
as community-based counselling with NRT, were eligible, as were studies that used
pharmacotherapy as a comparison or control intervention to psychological interventions.
We anticipated that these would be prominent in the literature given that NICE (2013) in
the United Kingdom and DHHS (2008) in the United States recommend the provision of
pharmacotherapy and psychological treatments for smoking reduction in mental health
services.
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Trials involving exercise as the sole intervention were excluded as the focus of this
review was specifically on psychological interventions. NICE (2013) recommendations
for smoking cessation in people with mental health problems do not include physical
activity as an intervention but focus primarily on pharmacotherapy and behavioural/
psychological support. Despite the well-documented links between exercise and well-
being, previous systematic reviews have found limited evidence for the effectiveness of
physical activity on smoking cessation in healthy individuals (Ussher, Faulkner, Angus,
Hartmann-Boyce, & Taylor, 2019; Ussher, Taylor, West, &McEwen, 2000) and those with
alcohol addiction or physical health issues (Ussher et al., 2000). Moreover, due to the lack
of staff resources, and environmental or physical riskmanagement practices in psychiatric
wards (Shattell, Andes, & Thomas, 2008), exercise-focused interventions may be difficult
to implement for smokers with mental health problems. Physical activity is, therefore,
unlikely to be routinely offered to those with severemental health problems as a smoking
cessation intervention.
Outcome measures
Primary outcome measures were changes in smoking behaviour and included number of
cigarettes smoked per day; 7-day point prevalence abstinence (i.e., abstinence from
smoking for at least seven days); and continuous abstinence (i.e., abstinence for one
month or longer). Objective physiological measures such as biochemically verified
expired carbonmonoxidewere also included (Peckham et al., 2017). An interventionwas
considered effective on a certain outcome measure if the subsequent reduction in
smoking was statistically significant at the .05 level. We also considered substantive
changes that were non-significant, perhaps owing to small sample size. Given the putative
cognitive benefits of tobacco use for patients with schizophrenia and the view that
smoking cessation exacerbates psychiatric problems, measures of clinical symptoms and
general functioning at baseline and follow-up points were also of interest, although these
outcomes were not primary in this review (Taylor et al., 2014). Examples of outcomes
measured include symptoms of depression, anxiety, negative affect, and cognitive
functioning, as well as physical symptoms such as nausea, akathisia, headaches, and
tachycardia. Quality of life (QoL) was also included.
Study selection and data extraction
After importing results from each database to ‘Refworks’, titles and page numbers were
screened for internal duplicity by the first author, using the ‘exact duplicate’ function.
External duplicates were also checked using the ‘exact duplicate’ and ‘close duplicate’
functions. All study titles were screened by the first author, and papers that did not reflect
the nature of the reviewwere excluded. All remaining abstracts were independently read
by the first two authors. Papers meeting eligibility criteria were carried forward for data
extraction.
A data extraction form was adapted from the Cochrane Review Group’s data
extraction template (Higgins et al., 2011) and summarized the study, population, type of
intervention, adherence, and outcomes. Before the data extraction process began, the
first author pilot-tested the formon one RCT and no changeswere deemed necessary. The
first two authors carried out the data extraction independently on all selected studies
using full study reports. Information was extracted on (1) participants’ characteristics
(including age, sex, ethnicity, number of cigarettes smoked per day, and specific mental
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health problem); (2) intervention type, setting, duration, mode of delivery, and dosage (if
involving pharmacotherapy); (3) length of follow-up; and (4) type of outcome measure
(i.e., number of cigarettes smoked per day, 7-day point prevalence, continuous
abstinence, and change in CO expired). Any disagreements were resolved through
discussion. Thirteen papers were included in the review after being assessed for full
eligibility in the data extraction stage. Of these, one pilot RCT (Evins et al., 2001) and its
subsequent RCT (Evins et al., 2005) were both included as they were conducted
separately and with different participants.
Assessment of bias in included studies
The Cochrane risk of bias tool (Higgins et al., 2011)was used to assess the internal validity
and risk of bias across seven domains. Risk of bias for each domain and an overall risk of
bias (low, high, unclear) for each study were independently allocated to each of the 13
eligible RCTs by the first two authors (Table 1). Comparison of the overall risk of bias for
each of the 13 studies revealed perfect agreement (100%) between the two reviewers
indicating excellent inter-rater reliability.
Data synthesis
Heterogeneity of the studies was assessed by the first two authors by blind inspection of
the data extraction findings and characteristics of the included studies. Between-study
variabilitywas assessed in relation to participants’ diagnoses; type of intervention; setting,
frequency, duration, and delivery format of the intervention; sample size; time of follow-
up; and outcome measures. Assessment of the between-study variability was guided by
our research questions and the data extraction form used for the assessment of the
included studies. Therewasmarked heterogeneity in a number of study-specific variables:
For example, sample sizes ranged from 9 to 151 participants per condition; duration of
interventions ranged from 1 week to 24 weeks, whereas duration of individual sessions
within an intervention ranged from 5 to 90 min; some interventions consisted of one
single session and others of a total of 24 sessions; and some interventions offered group
sessions, others individual, and one a combination of the two. There was also
heterogeneity in the risk of bias and in the outcome measures reported: Some studies
reported continuous abstinence from smoking, others smoking reduction from baseline,
and others 7-day point prevalence. In addition, time of follow-up ranged between studies
from four weeks to one year post-intervention. The result of this clinical and
methodological heterogeneity was that, even when outcome measures and conditions
were similar, one or more other confounding factors were likely to render comparisons
and pooling of data across studies inappropriate. As the Cochrane Effective Practice and
Organisation of Care (EPOC) (2017) group advises, ‘Reasons for not calculating an average
effect across studies include: Unexplained heterogeneity that make the average effect
difficult to interpret and potentially misleading [and] Differences in populations,
interventions, comparisons or methods that would make the average effect across
studies meaningless’ (p. 1). For these reasons, the research questions are addressed here
by presenting structured syntheses of the available evidence.
Data from the included studies were synthesized by considering change in smoking
behaviour between (1) the target quit date and the end of the intervention and (2) the
target quit date/end of intervention and post-intervention follow-up (short, medium, and
long term), with, where available or when calculation was possible, effect sizes and
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p-values. Short-term follow-up was any measurement of cessation taken up to 23 weeks
post-intervention/target quit date. Medium-term follow-up referred to any duration
between 24 and 51 weeks post-intervention. Follow-up at 52 weeks or more post-
intervention was regarded as long term.
Results
The electronic database searches yielded 6,189 results in total, and the grey literature,
hand journal, and reference list searches elicited a further 11 results. After duplicateswere
removed, a total of 5,207 papers were screened for eligibility, and of those, 5,126 were
removed after title screening. Any papers that had ambiguous titles were put forward to
the full-text review stage, at which 81 papers were considered for eligibility. Of these, 68
papers were excluded due to failing to fulfil eligibility criteria and 13were included in the
final review (Figure 1). Table S1 shows the reasons for exclusion of studies at the full-text
review stage.
No studies were excluded for having a high or unclear risk of bias. Of the six studies
with high risk, sources of bias included small sample size and differences in physiological
measures taken between patients (Evins et al., 2001); no blinding of participants (Baker
et al., 2015; Gilbody et al., 2015; Williams, Steinberg, Zimmermann, Gandhi, Stipelman,
Dooley Budsock,&Ziedonis, 2010); incomplete outcome data (Morris,Waxmonsky,May,
Tinkelman, Dickinson, & Giese, 2011); randomization procedure with allocation
concealment bias (George et al., 2000); and inconsistent or missing information on use
or dosage of NRT (Baker et al., 2006; Steinberg, 2003).
Study characteristics
Table 2 summarizes the key characteristics of the 13 studies included in this review. A
total of 1,497 participants were involved. All studies recruited participants with a severe
mental health diagnosis, and all included patients with schizophrenia or schizoaffective
disorder. Five also included participantswith bipolar disorder, ofwhich one (Morris et al.,
2011) also included patients with anxiety or depression. Of the 11 studies that reported
the setting of theintervention, 10 recruited participants from outpatient/community
mental health centres. Only one recruited participants from a secure psychiatric unit and
continued with the intervention after their discharge to a community mental health
centre. The majority of studies (77%) were conducted in the United States, two in
Australia, and one in the United Kingdom. The mean age of participants was 43.6 years,
they smoked an average of 25.7 cigarettes a day, and the majority (70%) were Caucasian.
Around 60% were male, a figure that reflects the higher prevalence of schizophrenia
spectrum disorders and of smoking among American men (Centers for Disease Control
and Prevention, 2015).
Information on the delivery of the psychological interventions was given in all except
one study (George et al., 2000) with varying degrees of detail. In studies that provided
such information, therapists were health care professionals (e.g., nurses, therapists, and
psychologists) trained in the delivery of the psychological interventions.
Table 3 summarizes the key findings from the included studies. The result columns
include the measures most commonly reported: abstinence (continuous abstinence and/
or 7-day point prevalence) and reduction in smoking by at least 50%.
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Narrative analysis
Question 1: Are psychological interventions independently effective? was addressed by
two studies that compared psychological interventions with controls (Gilbody et al.,
2015; Steinberg, 2003) and one in which group counselling and Quitline plus NRT were
compared with Quitline plus NRT (Morris et al., 2011).
Gilbody et al. (2015) compared patients with severe mental health problems
participating in a bespoke smoking cessation programme – that included home visits and
face-to-face support after unsuccessful quit attempts – with controls who were offered
advice on NHS smoking cessation services. Participants in the intervention group were
more likely than controls to have used NRT (44% vs. 19%) or varenicline (4% vs. 0%). At 1,
6, and 12 months, the intervention group had significant reductions in numbers of
cigarettes smoked per day, and at one and sixmonths significantly greater reductions than
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Figure 1. PRISMA flow diagram summarizing the results of the search.
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the control group, in which the reduction was significant at six months only. Although at
12 months group differences between proportions of quitting participants (36% vs. 23%)
were not significant, when adjusted for sex, age, baseline number of cigarettes smoked,
and alcohol consumed, the intervention groupwas almost three times more likely to have
stopped smoking than controls (odds ratio: 2.9, 95% CI: 0.8-10.5).
Steinberg (2003) compared two treatment groups – motivational interviewing (MI)
and psychoeducation –with a control group who received brief advice on quitting. Both
interventionswere associatedwithmodest but significant reductions inmean numbers of
cigarettes smoked per day 4 weeks post-intervention compared with baseline. The
control group, in contrast, showed no reduction. A mixed ANOVA indicated no
differences between the three groups, although paired t-tests suggest that, had the control
group been larger (n = 12), or the ANOVA been limited to four weeks only (rather than
one and four weeks), then both interventions would have been effective compared with
the control group.
Morris et al. (2011) combined 10 group counselling sessionswithQuitline counselling
(five telephone calls assistingwith quit attempts and relapse prevention) and 12 weeks of
NRT for patients with schizophrenia, bipolar disorder, depression, and anxiety. They
tested this programme’s effectiveness compared with Quitline with NRT only. At
24 weeks, the two groups showed similar significant reductions in mean number of
cigarettes smokedper day, but 21%of thosewho received group counselling, versus 8%of
those who did not, reduced this number by at least 50%.
Question 2: Are psychological interventions plus NRT effective? was addressed by
two studies that compared the effectiveness of a psychological intervention combined
with NRT versus standard care in inpatients (Prochaska, Hall, Delucchi, & Hall, 2014) and
outpatients (Baker et al., 2006) with a psychotic disorder. In Prochaska et al. (2014), the
intervention group (motivation tobacco cessation + NRT) showed significantly higher 7-
day point prevalence when abstinence rates were modelled over 18 months. In Baker
et al. (2006), the intervention group (MI + CBT + NRT) showed significantly more
continuous abstinence and 7-day point prevalence at 12-week follow-up and marginally
more continuous abstinence at 52 weeks. Reduction in the number of cigarettes smoked
of 50%ormorewas significantly greater in the intervention group at 12, 24, and 52 weeks.
Smoking reduction was clearly linked with treatment session attendance (Baker et al.,
2006). Patients who attended all 10MI/CBT sessions had better outcomes comparedwith
those receiving standard care in (1) continuous abstinence at 12-week follow-up (21.4%
vs. 4.0%), p < .001; (2) 7-day point prevalence at 12 weeks (30.0% vs. 6.0%), 24 weeks
(17.9% vs. 4.0%), and 52 weeks (19.0% vs. 7.0%), all ps < .001; and (c) number of
cigarettes smoked per day reduced by at least 50% at 12 weeks (57.1% vs. 16.6%),
24 weeks (41.4% vs. 18.5%), and 52 weeks (47.1% vs. 17.9%), all ps < .001. Moreover,
NRT use was related to attendance: in the treatment group, approximately 90% of high
attenders used NRT compared with 58.6% of low attenders.
Question3: Are psychological interventions combinedwith pharmacotherapymore
effective than psychological interventions alone?was addressed by four studies inwhich
CBT and pharmacotherapy were compared with CBT and placebo. Evins et al. (2001,
2005, 2007) administered either bupropion or placebo for 12 weeks to participants with
schizophrenia spectrum disorder. In two studies (Evins et al., 2005, 2007), they also
received weekly CBT sessions for the same period and in the third study (Evins et al.,
2001) for the first 9 weeks. In Evins et al. (2007), all participants also received high-dose
nicotine patches and gum.
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In two of the studies (Evins et al., 2001, 2005), 7-day point prevalence abstinence in
the CBT plus placebo groups even during treatment was negligible or absent. In the third
study (Evins et al., 2007), 19%of participants in the CBTplus placebo group showed 7-day
point prevalence, the difference between studies possibly indicating a small effect ofNRT.
However, in all three studies the CBT plus placebo groups showed clearer indication of
reduction in numbers of cigarettes smoked per day. For example, at week 12 (when
treatments were discontinued) the number of cigarettes smoked per day was reduced by
40%, and at 6 months by almost a quarter (23.6%) in one study (Evins et al., 2005), and by
11.9% in a later study (Evins et al., 2007). Further evidence of the short-term effectiveness
of CBT is suggested by the CBT plus placebo group showing a 42% increase in expired-air
CO between week 8, when CBT was discontinued, and week 12 (Evins et al., 2001).
A later study (Evins et al., 2014) focused on relapse prevention following 12 weeks’
administration of CBT and varenicline. At that point, one group continued with both
treatments, while the other switched to CBT plus placebo. At week 52, when the trials
were discontinued, 15% of the CBT plus placebo group showed continuous abstinence,
and at week 76, 10%. Reduction in number of cigarettes smoked was not reported in this
study.
All four of the Evins studies reported higher rates of abstinence when CBT was
combinedwith pharmacotherapy rather than placebo. In three studies (Evins et al., 2001,
2005, 2007), this effect was relatively short-lived and relapse rates were high; in one study
(Evins et al., 2007), 77% had relapsed after 12 months. But in the latest study (Evins et al.,
2014), when treatment continued for a year, 40% of participants taking varenicline
showed continuous abstinence at week 64, compared with 11% in the placebo group.
Earlier studies (Evins et al., 2001, 2007) also report evidence of longer-term reduction in
number of cigarettes smokedwhen bupropionwas administered: At 24 weeks, four times
as many in this group smoked 50% or fewer cigarettes daily as in the placebo group (Evins
et al., 2007).
Question 4: Which psychological interventions are most effective? Steinberg (2003)
and Steinberg, Williams, Stahl, Dooley Budsock, and Cooperman (2016) compared two
different types of psychological interventions. They reported that reduction in number of
cigarettes smoked daily did not differ between smokers having brief MI vs. psychoed-
ucation (Steinberg, 2003) and that continuous abstinence did not differ between smokers
who had brief MI with personalized feedback vs. interactive education (Steinberg et al.,
2016). In Steinberg (2003), both interventions resulted in patients smoking approxi-
mately 20% fewer cigarettes at four weeks compared with baseline.
Three studies compared the effectiveness of two different types of intervention for
smoking cessation, also including NRT (Baker et al., 2015; George et al., 2000; Williams
et al., 2010). Two of these indicate that abstinence and reduction in number of cigarettes
smoked daily did not differ between smokers receiving two different intensities of
behavioural counselling (24 weeks vs. 9 weeks) or face-to-face healthy lifestyle sessions
vs. telephone monitoring (Williams et al., 2010 and Baker et al., 2015 respectively). In
contrast, George et al. (2000) reported that behavioural therapy with supportive
counselling was more effective than specialized schizophrenia smoking treatment with
17.6% versus 10.7% (p = .03) of patients achieving abstinence at 24 weeks post-
intervention, respectively.
Baker et al. (2015) and Williams et al. (2010) reported that, regardless of intervention
type, there were significant reductions from baseline in the number of cigarettes smoked
at 15 and 52 weeks and at 17 weeks post-intervention, respectively. These two studies
also found that, irrespective of intervention type, there was a significant association
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between the number of sessions attended and smoking cessation. Baker et al. (2015)
reported that more smokers with high attendance (9–17 sessions) of face-to-face and
telephonemonitoring groups showed a reduction in cigarettes smoked of 50% or more at
15 weeks (51% vs. 16%) and 52 weeks (25% vs. 6.9%) than lower attenders. Similarly,
Williams et al. (2010) reported that smokers who attended more than two-thirds of
sessions were four-to-six times more likely than low attenders to be abstinent at three
months post-intervention (30% vs 8% for treatment of addiction to nicotine in
schizophrenia – TANS – and 43% vs 7% for medication monitoring – MM).
Question 5:What is the impact of psychological interventions on clinical symptoms?
With few exceptions (Evins et al., 2001; Gilbody et al., 2015), and regardless of
intervention type, duration, intensity, or combination with pharmacotherapy and/or
NRT, no negative effects on clinical symptoms were reported in the included studies
(Table S2). Four studies reported that, for patients in the intervention groups, there were
no changes between baseline and follow-up scores in psychiatric symptoms (Baker et al.,
2015; Evins et al., 2007; George et al., 2000; Williams et al., 2010) and psychosis, mood
symptoms, andpositive andnegative symptoms in schizophrenia (PANSS) (Williams et al.,
2010). Two studies reported that there were no serious adverse effects as a result of the
intervention (Evins et al., 2007, 2014), and one that patients in the intervention group had
a significantly lower likelihood of psychiatric hospitalization than controls (Prochaska
et al., 2014). Five studies reported either a trend towards (Evins et al., 2005) or a
significant improvement in psychiatric, depressive, and negative symptoms (Evins et al.,
2001), depression (Baker et al., 2006, 2015), mental functioning (Baker et al., 2006), and
physical and mental health quality of life (QoL) (Morris et al., 2011) in the intervention
groups.
In the earliest Evins et al.’s (2001) study, the group receiving CBT and placebo showed
an improvement in positive symptoms but a worsening of depressive symptoms, and a
non-significant increase in psychiatric symptoms. The CBT plus bupropion group did
better than the CBTplus placebo group on psychiatric and depressive symptoms. Gilbody
et al. (2015) reported higher deterioration in mental health in a number of smokers in the
intervention group compared with controls (15 versus 6), but the deterioration was
related to the intervention for only three participants from each group.
Discussion
Thirteen smoking cessation RCT studies published since 1999 were identified that
involved psychological treatment of people with mental health problems. Of these, only
three included control conditions for psychological interventions (Gilbody et al., 2015;
Morris et al., 2011; Steinberg, 2003). Morris et al. (2011) reported that counselling with
Quitline and NRT were more effective1 than Quitline and NRT alone. In Gilbody et al.
(2015), the intervention was confounded with NRT such that either the psychological
intervention, or NRT, or both, was effective, and in Steinberg (2003), no differences were
found, perhaps because the control group was too small (n = 12).
However, all of these three studies reported reductions in smoking from baseline –
rather than in comparison with controls – and these are consistent with psychological
interventions being effective. For example, in Steinberg (2003) both psychological
interventions –MI and psychoeducation – led to 20% reductions in number of cigarettes
1 For each study’s outcome measures, see the narrative analysis and Table 3.
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smoked. Similarly, five studies (Baker et al., 2006, 2015; George et al., 2000; Prochaska
et al., 2014;Williams et al., 2010) reported reductions in smokingwhen the psychological
treatments were administered, as did Evins et al. (2005, 2007) when psychological
treatments were administered without bupropion, although these might reflect only the
effect of NRT or of placebo. In contrast, Evins et al. (2001, 2014) reported no substantive
reduction in smoking when pharmacotherapy was not used, indicating that CBT was
ineffective in these studies. Similarly, the absence of substantive changes in Steinberg
et al. (2016) suggests either that MI and interactive education are ineffective, or that they
are ineffective in low dosages (a single 45-minute session).
The weight of the evidence from these 12 studies is therefore at least consistent
with that of Morris et al. (2011) and indicates that a range of psychological
interventions are effective in reducing smoking when used by smokers with mental
health problems. Unfortunately, since none of these 12 studies included an adequate
control group, this evidence can only be considered circumstantial. The answer to the
first research question, regarding whether psychological interventions are effective, is
therefore ‘probably’.
The second research question concerned whether psychological interventions plus
NRT are effective. Two studies addressed this question (Baker et al., 2006; Prochaska
et al., 2014). Although there was little evidence of increased abstinence in Baker et al.
(2006), there was a clear and substantial difference in proportions of participants who
reduced their smoking by 50% or more. Similarly, Prochaska et al. (2014) reported more
abstinence when psychological treatment was combined with NRT compared with usual
care. Although we cannot tell in either case whether the psychological treatment, or the
NRT, or both, was effective, these two studies make a strong case for offering NRT when
administering psychological interventions.
The third research question – are psychological interventions combined with
pharmacotherapymore effective thanpsychological interventions alone? –was addressed
in a series of studies by Evins and colleagues. They showed that CBT plus bupropion is
more effective in reducing smoking than CBT alone (Evins et al., 2001, 2005, 2007) and
that CBT with varenicline effectively reduces relapse (Evins et al., 2014).
The fourth research question concerned which psychological interventions are most
effective, and was directly addressed in five studies. Four reported equal effectiveness
(Baker et al., 2015; Steinberg, 2003; Steinberg et al., 2016;Williams et al., 2010). Although
George et al. (2000) reported that general behavioural therapy was somewhat more
effective than specialized behavioural therapy, most of the evidence indicates that the
different types of psychological intervention are approximately equally effective.
Whether interventions incorporate MI, CBT, personalized feedback, psychoeducation,
behavioural counselling, or medication management, the evidence suggests that they all
increase the likelihood of smoking reduction or abstinence in patients withmental health
problems.
Perhaps this indicates a Hawthorne effect such that any intervention of any form is
effective. A more optimistic explanation is that the feature that all these therapies have in
common – namely talking and thinking with skilled and supportive clinicians about
smoking and its consequences – is equally effective, regardless of how it is structured and
implemented. This explanation is consistent with the ‘common factor theory’, according
to which different psychotherapy approaches have similar benefits because of the core
ingredients they share: the formation of an alliance between therapist and patient; the
creation of expectations through explanation of a problem and the treatment involved;
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and the consensus about health behaviours that patients are likely to adopt (Imel, &
Wampold, 2008; Wampold, 2015).
CBT, MI, behavioural counselling, personalized feedback, and monitoring are
examples of effective interventions in the reviewed trials that share these core
psychotherapeutic ingredients, in particular the formation of an alliance between
therapist and patient. This was also reflected in Steinberg et al.’s (2016) trial, which
indicated a positive association between patients’ rating of their alliance with their
therapist – through the client version of the Working Alliance Inventory (WAI-C) – and
their reported motivation to quit, irrespective of intervention type. Nevertheless, the
designs of the reviewed studies do not allow us to disentangle the effects of the different
psychotherapeutic ingredients for smoking cessation in this group of patients and so this
interpretation can only be tentative.
Our findings also provide some evidence of a strong dose–response relationship. Baker
et al. (2015) and Williams et al. (2010) found better attendance leading to higher rates of
abstinence and smoking reduction in all four of the conditions they reported. This
evidence supports the view that psychological interventions are effective, although it
might also be explained by better-motivated patients being those who are most likely to
attend sessions and to succeed in quitting smoking. The initial evidence from three of the
reviewed studies, which measured patient readiness to change and motivation to quit
smoking (Prochaska et al., 2014; Steinberg, 2003; Steinberg et al., 2016), suggests that
both are good predictors of engagement with smoking cessation interventions. It is also
worth noting that one study indicated that psychological interventions can be effective
even when patients score low on the readiness to change scale; Prochaska et al. (2014)
reported that although at the start of their trial very few participants were ready and
intended to quit smoking, abstinence increased during the intervention, indicating
engagement in the quitting process.
It is also noticeable that in these three studies, interventions included small numbers of
short sessions. For example, in Steinberg et al. (2016) participants had only one 45-minute
session of either MI or interactive education. Had these interventions been more intense,
over a longer period, then it is possible that they would have proven more effective. In
contrast, Williams et al. (2010) administered 24 45-minute sessions to one of their
behavioural counselling conditions (TANS), compared with nine 20-minute sessions to
their other (MM) group, but found them to be equally effective.
A similar point is that in some studies, psychological interventions were
administered to groups and in others to individuals. Further research is required to
assess the relative clinical effectiveness and cost-effectiveness of these interventions
according both to dosage (intensity and duration) and to mode of administration (to
groups or individuals).
The fifth research question concerned the impact of interventions on clinical
symptoms. The evidence reviewed here does not support the presumption made by
some health care professionals that smoking cessation interventions may have adverse
effects on the psychological state of smokers with mental health problems. On the
contrary, most reviewed interventions resulted in either no change, or improvement
in psychiatric symptoms. This is consistent with evidence from Peckham et al. (2017)
and Taylor et al. (2014), both of which indicated that smoking cessation in people
with severe mental health problems is associated with a significant reduction in
adverse mental health symptoms and improvements in depression, positive affect, and
quality of life. It is also consistent with evidence from the general population, in
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which smoking cessation is associated with improved mental health (Taylor et al.,
2014).
Limitations and future research
Of the 13 studies, only two (Baker et al., 2006; Prochaska et al., 2014)were judged to have
a low risk of bias overall. This point further reduces confidence in the findings of the
remaining studies, and hence in our ability to draw clear and definitive conclusions
regarding the answers to all research questions except the second (the effectiveness of
psychological interventions combined with NRT), which both studies with low risk of
bias addressed.
A second limitation is that there is too little evidence available to compare the
effectiveness of interventions across mental health diagnoses that vary in nature and
severity. The reviewed studies did not provide such direct comparisons. However,we can
be confident that the generally positive outcomes of psychological interventions apply at
least to smokers with schizophrenia and/or schizoaffective disorder and bipolar disorder.
This is because all 13 studies included participants with schizophrenia and/or schizoaf-
fective disorder, and five also included participants with bipolar disorder. Only one study
(Morris et al., 2011) included smokers with depression or anxiety (who made up
approximately 50% of the sample) in addition to smokers with schizophrenia or bipolar
disorder.
In this review, Morris et al.’s results were compared with those reported by Steinberg
(2003) and Gilbody et al. (2015) because all three studies addressed the first of the
research questions. Steinberg’s and Gilbody et al.’s samples included smokers with
schizophrenia or schizoaffective disorder, and Gilbody et al.’s samples also included
patientswith bipolar disorder.While direct comparisons of the studies’ results are difficult
because different outcome measures were recorded at different times, all three studies
demonstrated reductions in smoking in the short and/or medium term in the intervention
groups, suggesting that the participants’ different diagnoses are unlikely to have had a
great impact on the findings. Nonetheless, it is possible that smokers with schizophrenia
are best treated using one type of intervention, and thosewith depression or anxiety using
another. The heterogeneity of diagnoses and needs of people with mental health
problems, and its implications for smoking cessation programmes, remain key issues for
future investigation.
Third, the heterogeneity of the included studies in terms of type, duration, and
intensity of intervention, participant diagnoses, where participants were recruited from
(i.e., inpatients or outpatients), and outcome measures mean that meta-analysis or even
meaningful statistical comparison between studies of intervention effectiveness is not yet
possible given the available evidence. The result is that sample sizes are limited to those of
individual studies and that therefore our conclusions should only be generalized to other
populations and settings with particular caution.
Future researchers are encouraged to help address each of these points, and in
particular to design properly controlled experiments that enable us to assess the
independent effectiveness of psychological interventions in this population. Other
important questions that cannot yet be answered given the available evidence concern the
relative effectiveness of interventions according to who they are delivered by (e.g.,
psychologists, psychiatrists, or other health care professionals), how they are delivered
(e.g., to groups or individuals, in clinical settings or at home, face-to-face or by phone), and
to whom (according to type and severity of diagnosis).
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Conclusion
The available evidence is consistent with a range of psychological treatments of smoking
by people with mental health problems being independently effective. But much of this
evidence is circumstantial, and only one of the 13 studies reviewed here addressed this
issue directly. Our understanding of which of these treatments are effective, how they
should be administered, and to which mental health populations remains poor.
Considering the implications for the well-being of the high proportions of smokers with
mental health problems, further research – in the form of properly designed RCTs – is
urgently required.
However, there is good evidence that some psychological interventions are effective
when used in combination with NRT or pharmacotherapy. Effective interventions
probably include CBT, MI, behavioural counselling, personalized feedback, and
monitoring, and the available evidence suggests approximately equal effectiveness. A
key psychotherapeutic ingredientmight be the formation of an alliance between therapist
and patient. It is also clear that there is a strong dose–response relationship: Increased
attendance predicts improved outcomes, and telephone-based and relatively brief
interventions seem to be as effective as more intense and longer-term ones. We can be
confident, too, that there are few negative psychological or physical side effects of these
treatments. On the contrary, these must be weighed against the reports of positive side
effects plus, of course, the unquestionable benefits to the short- and long-termwell-being
accrued by almost everyone from reducing or quitting smoking.
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